注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Olema Pharmaceuticals Inc是一家臨床階段的生物製藥公司。該公司專注於女性癌症靶向療法的發現、開發和商業化。其主要候選產品OP-1250是一種口服療法,具有完全雌激素受體(ER)拮抗劑(CERAN)和選擇性ER降解劑(SERD)的聯合活性。OP-1250是治療內分泌驅動型癌症的口服小分子臨床階段候選產品。它的設計基於對ER的結構理解。OP-1250作為一種單一療法,並與細胞週期蛋白依賴性激酶4和6(CDK4/6)抑製劑聯合使用,在幾種異種移植模型(包括乳腺癌腦轉移模型)中顯示出強烈的腫瘤收縮。這是在轉移性ER陽性(ER+)、人表皮生長因子受體2陰性(HER2-)乳腺癌患者中進行的I期/II期臨床試驗,以及與palbociclib聯合進行的I期臨床試驗。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Gorjan Hrustanovic | 35 | 2018 | Independent Director |
Frank P. McCormick | 74 | 2014 | Chairman of Scientific Advisory Board |
Sandra J. Horning | 75 | 2020 | Independent Director |
Sean W. Fanning | - | - | Member of Scientific Advisory Board |
Mark Sliwkowski | - | - | Member of Scientific Advisory Board |
Christopher C. Benz | - | - | Member of Scientific Advisory Board |
Scott Garland | 55 | 2023 | Director |
Cynthia Marie Butitta | 70 | 2020 | Independent Director |
Yi Larson | 43 | 2021 | Independent Director |
Pamela M. Klein | 63 | 2020 | Member of Scientific Advisory Board |
Cyrus L. Harmon | 53 | 2006 | Director |
Andrew S. Rappaport | 65 | 2013 | Independent Director |
Sean P. Bohen | 57 | 2020 | President, CEO & Director |
Graham Gordon Walmsley | 37 | 2020 | Independent Director |
Ian T. Clark | 64 | 2020 | Independent Chairperson of the Board |
Pamela Munster | - | - | Member of Scientific Advisory Board |
Jeffrey Hager | 59 | - | Member of Scientific Advisory Board |
Geoffrey Greene | - | - | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核